Literature DB >> 23464582

[Effects of the population screening into breast cancer].

André L M Verbeek1, Mireille J M Broeders, Suzie J Otto, Jacques Frachebou, J D M Hans Otten, Roland Holland, G J Ard den Heeten, Harry J de Koning.   

Abstract

Annually, in the Netherlands around 900,000 women between the ages of 50-75 years undergo mammography as part of a population screening into breast cancer. In this way more than 5000 cases of breast cancer are detected (0.6% of women screened); 70% of these malignancies are < stage II, which is prognostically favourable. Due to the early detection and treatment of breast cancer, the breast cancer death risk in those women who participate in the population screening is half that of women who choose not to be screened. The downside of the population screening is that participants are relatively often referred to a hospital for a diagnostic work-up (around 2%), and 70% of them are ultimately found not to have cancer. The positive predictive value of the population screening is 30%. Early discovery also leads to over-diagnosis in patients with breast cancer that without screening would never have manifested itself. Based on computer simulations it has been estimated that in the Netherlands over-diagnosis occurs in 9% of patients in whom breast cancer is detected during a population screening.

Entities:  

Mesh:

Year:  2013        PMID: 23464582

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  2 in total

1.  Simplifying Breast Imaging Reporting and Data System classification of mammograms with pure suspicious calcifications.

Authors:  Gisela Lg Menezes; Gonneke Ao Winter-Warnars; Eva L Koekenbier; Emma J Groen; Helena M Verkooijen; Ruud M Pijnappel
Journal:  J Med Screen       Date:  2017-07-10       Impact factor: 2.136

2.  Minimally invasive breast cancer excision using the breast lesion excision system under ultrasound guidance.

Authors:  W B G Sanderink; L J A Strobbe; P Bult; M S Schlooz-Vries; S Lardenoije; D J Venderink; I Sechopoulos; N Karssemeijer; W Vreuls; R M Mann
Journal:  Breast Cancer Res Treat       Date:  2020-08-01       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.